

Maryland Medicaid's Maternal Opioid Misuse Model—Best Practices and Expectations for Case Management, Staffing and Workflow

Version 5.0 (9 June 2022)

Version	Date	Change Log
1.0	1/25/21	N/A
2.0	4/14/21	Case management workflow timeline, self-report question list, and further Release of Information requirement information added; included guidance on data and document storage and case management appointment locations
3.0	6/9/21	Further guidance on CCM access, ROI completion, OUD diagnosis requirement and self-report template provided; eligibility checklist for MOM enrollment added
4.0	11/17/21	Updated OUD diagnosis requirement and related checklist; clarified expectations around substance use treatment engagement; added guidance on inpatient stays
5.0	5/31/22	Changed in-person requirement to preference; added additional timelines for documentation; added Maryland Prenatal Risk Assessment as a source of opioid use confirmation; removed limited to St. Mary's County; removed references to self-report template (now built into MOM CCM); updated case management documentation requirements

Executive Summary

The purpose of this document is to outline the accepted case manager provider types, staffing related needs and expectations, as well as workflow to fulfill the case management aspect of the Maternal Opioid Misuse (MOM) model. This document is meant to be used as a resource for MCOs to refer to while finalizing their staffing plans and preparing for implementation. Additionally, the case management workflow section of this document provides a detailed overview of the associated tasks required at various points during a participant's engagement in the model to fulfill the requirements needed to receive per member per month (PMPM) payments.

Background

The Maryland Department of Health (the Department) launched its MOM model in January 2020, with funding from the Center for Medicare and Medicaid Innovation (CMMI) and in collaboration with the Centers for Medicare and Medicaid Services (CMS). The MOM model focuses on improving care for pregnant and postpartum Medicaid participants diagnosed with opioid use disorder (OUD). Substance use is a leading cause of maternal death and has a significant impact on the approximately 1,500 infants born to Medicaid participants with OUD in Maryland per year. Maryland's MOM model addresses fragmentation in the care of pregnant and postpartum Medicaid participants with OUD tin Maryland per year. Maryland's MOM model addresses fragmentation in the care of pregnant and postpartum Medicaid participants with OUD through collaborative efforts with its managed care organizations (MCOs), improved data infrastructure and strengthened provider capacity in underserved areas of the state. The MOM model aims to increase utilization of physical and behavioral health care services, such as medication for opioid misuse disorder (MOUD), as well as to address health-related social needs, for this population through enhanced MCO case management.

Best Practices

Case Management

The Substance Abuse and Mental Health Services Administration (SAMHSA) has described *case management* as a coordinated approach to the delivery of health and social services, linking clients with appropriate resources to address specific needs. SAMHSA notes that effective case management consists of the following set of functions: (1) assessment; (2) planning; (3) linkage; (4) monitoring; and (5) advocacy.¹ Similarly, *case manager* has been defined as an individual responsible for executing case management activities, including assessment of needs, service planning, service plan implementation, service coordination, monitoring and follow-up, reassessment, case conferencing, crisis intervention, and case closure.²

Case Managers can serve as a single point of contact for participants who receive services from various entities. For the purposes of the Maryland MOM model, MOM case managers will serve as the "quarterback of care," ensuring participants enrolled in the MOM model not only receive needed health care services but also gain access to and remain connected to appropriate social services in the community. The overarching goal of comprehensive and coordinated case

¹ Center for Substance Abuse Treatment. Comprehensive Case Management for Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series, No. 27. HHS Publication No. (SMA) 15-4215. Rockville, MD: Center for Substance Abuse Treatment, 2000. Retrieved from: <u>https://store.samhsa.gov/system/files/sma15-4215.pdf</u>

² New York State Department of Health AIDS Institute. Standards for HIV/AIDS Case Management. 2006. Retrieved from: <u>https://www.health.ny.gov/diseases/aids/providers/standards/casemanagement/docs/casemanagementstandards.pdf</u>

management is to reduce barriers that impede access to and/or compliance with treatment. Research has shown that retention in Substance Use Disorder (SUD) treatment is more likely when other social needs are addressed concurrently.³ Such needs include, but are not limited to: housing supports, food assistance, vocational services, educational resources, transportation, child care, legal assistance and peer support.⁴

Other best practices for case management through the MOM model involve:

- Developing and revisiting MOM care plans during case management encounters preferably face-to-face meetings—and negotiating between MOM model participants and MOM case managers to encourage active participation and empowerment;
- Jointly developing measurable goals and activities—taking into consideration the participants' cognitive and physical abilities, available resources, support networks and motivations—that result in a more realistic, MOM model participant-specific care plan;
- Offering a copy of the MOM care plan to the participant, reinforcing participant ownership and involvement in the case management process;
- Documenting changes or updates to the MOM care plan as well as actual outcomes to track MOM model participant progress;
- Engaging family members and the participant's support network to assist in ensuring a MOM model participant receives needed service, including inclusion in the MOM care plan to carry out activities;
- Strengthening data-sharing and communication between MCOs and the Behavioral Health Administrative Services Organization (BH ASO); and
- Building relationships between MCOs, Local Health Departments (LHDs), and Local Behavioral Health Authorities (LBHAs) to leverage unique local opportunities and programs for MOM model participants.

Staffing

While MCOs must include one or more Medicaid-approved qualified provider type as the designated MOM case manager(s) in their staffing model (see below for eligible provider types); MCOs may enlist lay health workers, such as community health workers (CHWs) and Certified Peer Recovery Specialists (CPRSs), to support engagement and outreach activities. CHWs typically belong to the same communities as the individuals they serve and are a provider type

³ Substance Abuse and Mental Health Services Administration. Substance Abuse Treatment: Addressing the Specific Needs of Women. Treatment Improvement Protocol (TIP) Series, No. 51. HHS Publication No. (SMA) 13-4426. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2009. Retrieved from: <u>https://store.samhsa.gov/system/files/sma15-4426.pdf</u>

 ⁴ Center for Substance Abuse Treatment. Medication for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series No.
 63. HHS Publication No. (SMA) 18-5063. Rockville, MD: Center for Substance Abuse Treatment, 2018. Retrieved from: https://medicine.yale.edu/edbup/quickstart/TIP_63_338482_42801_v1.pdf

that may be beneficial in improving the quality and cultural responsiveness of care.⁵ Similarly, CPRSs offer non-judgmental, practical information for individuals with OUD and provide unique insights through their lived experiences.^{6,7} Evidence demonstrates that utilization of peer recovery specialists and other paraprofessionals is a promising practice for continued engagement among individuals with OUD.⁸ As an illustrative example, a CPRS could perform the following functions:

- Naloxone education and distribution;
- Referrals to community resources-ongoing, warm handoffs at discharge;
- Appointment reminders, follow up calls, and assisting with eliminating barriers to accessing care (*i.e.*, transportation, child care);
- Outreach to disengaged MOM model participants; and
- Accompany to clinician visits with MOM model participants.

With regard to staffing ratios, the Improving Mood: Providing Access to Collaborative Treatment (IMPACT) model utilized one full-time case manager for a caseload of 100-120 participants. IMPACT case managers include clinical social workers, master's level counselors/therapists, nurses, and psychologists.⁹ Another, the Mental Health Integration Program (MHIP) had a typical caseload of 50-75 participants per one full-time case manager; however, larger caseloads were managed with support from community health workers. MHIP targets mental health and substance use conditions, and case managers include social workers and nurses.¹⁰ The Collaborative Care Model (CoCM) varies the caseload per full-time case manager based on the target population characteristics. The CoCM has substantiated that a full-time case manager could have a lower caseload of 60-80 participants if they were Medicaid enrollees diagnosed with behavioral health conditions and had limited social supports. CoCM

https://bha.health.maryland.gov/Documents/CPRS%20Overview%20Guide comms 030518.pdf

⁵ American Public Health Association. Community Health Workers. (n.d.). Retrieved from: <u>https://www.apha.org/apha-communities/member-sections/community-health-workers</u>

⁶ Certified Peer Recovery Specialists:

⁷ Dardess, P., Dokken, D. L., Abraham, M. R., Johnson, B. H., Hoy, L., & Hoy, S. (2018). Partnering with patients and families to strengthen approaches to the opioid epidemic. Bethesda, MD: Institute for Patient- and Family-Centered Care. ⁸ Ibid.

⁹ Unützer, J., Katon, W., Callahan, C., Williams, J., Hunkeler, E., Harpole, L., Langston, C. (2002). Collaborative Care Management of Late-Life Depression in the Primary Care Setting: A Randomized Controlled Trial. JAMA, 288(22), 2836-2845.

¹⁰ Vannoy, S., Mauer, B., Kern, J., Girn, K., Ingoglia, C., Campbell, J., Unützer, J. (2011). A Learning Collaborative of CMHCs and CHCs to Support Integration of Behavioral Health and General Medical Care. Psychiatric Services, 62(7), 753-758.

behavioral heath care managers include nurses, social workers, psychologists, and licensed counselors.^{11,12}

MOM Model Provider Types and Staffing

Provider Types

The provider types that may provide case management and care coordination services in Maryland Medicaid for the MOM model are as follows: physician, physician assistant, nurse practitioner, nurse midwife, registered nurse, licensed clinical social worker, psychologist, certified professional counselor, and psychiatric nurse. It is important to note that Maryland Medicaid does not currently reimburse for services rendered CHWs or CPRS. An MCO could consider using CPRS and/or CHWs in their case management staffing model, which could be supported by the PMPM rate for enhanced case management activities, although secondary supports are not a requirement for the model.

Staffing Ratios

As described above, the Department identified several integrated health models to gain an understanding of an effective participant-to-case manager ratio. Findings from the review conducted determined that while ratios summarized for these cited models were higher than the Department's expectations for the MOM model, none of the models had the service delivery and care coordination activities that will be required for case managers to conduct on a monthly basis. Due to this, MCOs should consider substantially lower staffing ratios to accommodate the case management level forecasted to ensure success of the model. It should also be noted that case management activities that will be required and outlined in this document represent a bundle of enhanced services different from those already offered to pregnant and postpartum MCO participants.^{13,14}

Bridging the gap between primary care, behavioral health treatment, obstetric care, and other social service needs requires a dedicated full-time case manager. Each MCO should employ or contract with qualified case managers to render the services described in this document. The

 $^{^{11}}$ AIMS Center. Guidelines on Caseload Size for Behavioral Health Care Managers and Psychiatric Consults. University of Washington: 2017. Retrieved from:

http://aims.uw.edu/sites/default/files/Behavioral%20Health%20Care%20Manager%20Caseload%20Guidelines_072120%20Fina I.pdf

¹² AIMS Center. Behavioral Health Care Manager. Retrieved from: <u>http://aims.uw.edu/collaborative-care/team-structure/care-manager</u>

¹³ COMAR 10.67.06.21: <u>http://www.dsd.state.md.us/comar/comarhtml/10/10.67.06.21.htm</u>

¹⁴ COMAR 10.67.04.08: <u>http://www.dsd.state.md.us/comar/comarhtml/10/10.67.04.08.htm</u>

number of case managers per MCO needed to implement the MOM model depends largely on the number of eligible participants within each MCO. The Maryland MOM model proposes having a ratio of one MOM case manager per 30 MOM model participants (1:30) due to the substantial amount of care coordination and associated tasks required by MOM case managers to fulfill the requirements of the MOM model (outlined below) and to adequately address the myriad social and health needs for this vulnerable population.

Additionally, while MCOs are charged with providing the MOM model enhanced case management and care coordination services described in this document, MCOs may choose to partner with other entities, such as LHDs, to provide the MOM services on the MCOs' behalf.

Case Management Workflow - Associated Tasks and Timeline

MOM case managers will need to conduct certain tasks throughout a participant's engagement in the model and ensure the fulfillment of model requirements within a timely manner to receive PMPM payments.

It is imperative that MOM case managers document all MOM related tasks within the MOM Care Coordination Module (CCM), hosted by CRISP, in addition to documentation that would normally occur separately within their native electronic health record (EHR). MOM case managers will need Wi-Fi or cellular access to use the CCM, a web-based portal. Continually updating this information for all assigned MOM model participants within the MOM CCM, on at least a monthly basis by the final day of the month, will be vital for MCOs to receive PMPM payments. Documentation within the MOM CCM will also play an essential role in the monitoring and evaluation components of the grant to measure the impact of model services, which is tied to the possibility of additional MOM milestone funding. Successful completion of MOM interventions could result in incentives through this type of funding.

Please use this guide as a reference for associated tasks to be completed during the phases of participant engagement and the timeline to ensure compliance with the model. This document may be updated periodically with supplementary tasks (*e.g.,* screening requirements) as needed, should CMMI request additional measures to be reported for grant monitoring and evaluation activities.

Pre-Enrollment: Referral Pathways and Eligibility Screening

• MCOs identify potentially eligible participants through the following avenues and forward referrals to MOM case managers:

- No wrong door referral from other agencies: LHDs, LBHAs, law enforcement, EDs, somatic and BH providers, DHS
- Screening, Brief Intervention and Referral to Treatment (SBIRT)
- o Maryland Prenatal Risk Assessment (MPRA)
- o MCO data-mining and enrollment screening
- o Referral from the BH ASO
- Referral from a community-services organization (CSO)
- o See also: Participant Engagement Strategies Brief
- MOM case managers receive referrals and contact identified potential participants to verify interest and confirm clinical eligibility (See Appendix A for an Eligibility Checklist)
 - Current MD state resident residing in a MOM service area
 - Current HealthChoice member
 - Currently pregnant (cannot enroll postpartum)
 - OUD Diagnosis Must have a formal OUD diagnosis, at any point in participant's medical history, have responded positively to opioid use on the MPRA or be willing to attest to a current or previous history of OUD¹⁵ before the participant enrolls into the model. (See Appendix B for additional guidance.)
- Schedule an intake appointment (preferably in-person)
 - Review approximate length of appointment and what to expect during session
 - In-person intake appointments could occur in the following locations, according to participant preference: MOM model participants' residence; private rooms in the local library; local health department; housing shelter or temporary housing (*e.g.*, motels); pregnancy centers; clinician offices; parks; unhoused encampments, or other locations as agreed upon by MOM participant and MOM case manager.
- Coordinate with the BH ASO to confirm Part 2 Release of Information completion

Participants must be enrolled during pregnancy prior to delivery as one aspect of eligibility. As part of a strategy for identifying participants, a goal of the MOM model will be to increase both the amount of MPRAs completed by providers in a timely manner as well as streamline the routing of MPRAs via ACCUs to MCOs to assist with identifying pregnant beneficiaries with OUD earlier in their pregnancy. Due to claims lag, the Department encourages MCOs to identify innovative ways other than data-mining to identify and recruit potentially-eligible participants on the front-end as part of their staffing plans for the MOM model. If data-mining is warranted, the following HCPCS codes are specifically related to prenatal care: H1000 and H1003. Please note the identification and use of these codes may not be a reliable method for identifying

 $^{^{15}}$ Self-attestation along with documented OUD screening will satisfy formal OUD diagnosis. This documentation must be captured in MOM CCM

potentially-eligible participants in a timely manner. Other approaches should be exhausted first.

It is important to note that, although the MOM model encourages participants to seek or maintain treatment for OUD, engagement in treatment is not a prerequisite for model eligibility and enrollment. Additionally, participants are welcome to continue in the model even if, over the course of their participation, they no longer have their infant for reasons such as adoption, CPS involvement and fetal demise.

To be considered eligible to participate in the MOM model, participants must have an OUD diagnosis before enrolling into the MOM model. To ascertain an OUD diagnosis, MCOs must look in their data for history of OUD-related codes for the potential participant; if no history is found, MCOs may consult with the BH ASO to look in its data. Appendix C outlines a list of ICD-9 and ICD-10-CM codes that constitute an OUD diagnosis for the purposes of the MOM model. The Department also accepts positive responses to the opioid use question on the MPRA as an OUD diagnosis for purposes of MOM model eligibility.

If a potential participant does not have a claims history or MPRA response that indicates an OUD diagnosis, MOM case managers will be advised to coordinate with the potential participant for a verbal self-attestation of current or previous history of OUD before enrolling into MOM model services. The self-attestation process is meant to address barriers to enrolling participants in a timely manner. MCOs may proceed to setting up an intake appointment while simultaneously following the search procedures to verify or confirm a claims history of OUD on these participants. MCOs will need to document attempts to identify OUD diagnosis - in managed care encounters and behavioral health claims - in the MOM CCM by the time of enrollment following the guidance outlined below for these participants.¹⁶

In the case that self-attestation is required, MOM case managers should administer the OUD screening tool (see Appendix B) with participants who self-report their OUD and document date screening was administered and level of severity to satisfy the formal OUD diagnosis requirement. In addition, if a MOM case manager is clinically-licensed to provide a diagnosis, they should record that information into the MOM CCM, according to the clinical OUD diagnosis indicators in Appendix C.

Case managers may opt to conduct the self-attestation with participants upon intake, as it may help to indicate level of opioid use and inform the care planning process.

¹⁶ Dates MCO checked their system and coordinated with Optum to verify OUD would be documented in the Medications and clinical conditions field of the MOM CCM intake form until an Other section can be built out in future enhancements

Figure 1 below displays the pre-enrollment workflow.




Figure 1. Pre-Enrollment Workflow

MCOs must also engage with the BH ASO and check for Part 2 release of information (ROI) to assist in verifying a participant's clinical eligibility during the pre-enrollment screening process. The BH ASO will collaborate with MOM case managers to ensure Part 2 ROIs are obtained for consenting MOM participants.

Table 1 below depicts a high-level summary of associated tasks and expectations throughout a participant's participation in the model. Additional detail follows the table.

Table 1. Case Management Workflow Timeline

	Pre-enrollment	Intake		Ongo	ing Enrollment		Substantial outreach	Discharge
Associated Activities	Month 0/Referral	Initial Visit/Month 1	Month 2	Months 3-8 (Third Trimester)	Postpartum (up to 60 days)	60 Days Postpartum- Infant's 1st birthday	Anytime/Multiple Periods of up to 2 Months	Final Enrolled Month
Screenings	Confirm interest and clinical eligibility: current MOM service area resident, HealthChoice member, pregnant, formal OUD diagnosis (or self- attestation)	All required intakes, HRSN (with depression, tobacco, alcohol embedded), PHQ-9 (if positive result from HRSN), GAD-7. PAM, Self-Report Template		During third trimester: HRSN (with depression, tobacco, alcohol embedded), PHQ-9 (if positive result from HRSN) PAM at 90 days	HRSN (with depression, tobacco, alcohol embedded), PHQ-9 (if positive result), GAD-7, Self-Report Template, NIDA ASSIST SUD	Every 3 months- HRSN (with depression, tobacco, alcohol embedded), PHQ-9 (if positive result)	N/A	HRSN (with depression, tobacco, alcohol embedded), PHQ-9 (if positive result), GAD-7
Monthly in- person visits/contact	Schedule intake appointment Contact BH ASO to confirm Part 2 ROI completion		At least one Core Component	At least one Core Component	At least one Core Component (provide at least health promotion component including providing naloxone post- delivery check-in)	At least one Core Component	At least 3 outreach attempts with two different methods, up to 2 months	At least one Core Component
Care plan and documentation	Document intake appointment date/time	New case development MOM CCM, Goal Creation (2-3 goals)	Goal Check In, MOM CCM documentation	Goal Check In, MOM CCM documentation	Goal Check In, MOM CCM documentation	Goal Check In, MOM CCM documentation	Document dates and outreach methods in MOM CCM	Review Goals, provide linkages, document activities and update discharged status in MOM CCM and send care alert

	Pre-enrollment	Intake		Ongo	ing Enrollment		Substantial outreach	Discharge
Associated Activities	Month 0/Referral	Initial Visit/Month 1	Month 2	Months 3-8 (Third Trimester)	Postpartum (up to 60 days)	60 Days Postpartum- Infant's 1st birthday	Anytime/Multiple Periods of up to 2 Months	Final Enrolled Month
MOM Participant responsibilities	Answer OUD Dx screening (if applicable) and eligibility questions, confirm Medicaid ID, and sign Part 2 ROI (if outstanding)		Have at least 1 BH or somatic visit	Have at least 1 BH or somatic visit	Have at least 1 BH or somatic visit	Have at least 1 BH or somatic visit	N/A	Have at least 1 BH or somatic visit

During Intake: First Month of MOM Participation

- Informed Consent
 - Explain program requirements and participant rights to voluntarily participate and withdraw, and answers any questions participants raise
 - Collect participant signature for informed consent and any other intake forms in addition to those required by the MOM model
- Initial Care Plan
 - Develop jointly during intake session
 - Confirm/collect participant contact information, denote preferred contact method, and emergency/secondary contacts
 - Confirm/collect information on all providers participant is currently under the care of and their contact information
 - Identify 2-3 goals based on participant identified areas of need, to be reviewed during every monthly meeting and updated as needed
- Screenings that must be completed within 7 days of model enrollment (The Department recommends these be conducted during the initial intake visit, as all components are required to enroll participants into the model and results of these screenings may influence the care plan.) (See Appendices C and D for additional detail.)
 - *HRSN screening* Administer MOM model adapted AHC screening tool located within CRISP.
 - Depression screening captured through HRSN screening tool using the same screening and scoring methodologies as the PHQ-2; administer the PHQ-9.
 <u>separately</u> and create a follow-up plan for those who screen positive (score of 3 or above on PHQ-2 questions).
 - Anxiety screening captured through <u>separate</u> GAD-7 screening, with indication of participant's level of anxiety documented.
 - *Tobacco screening* captured through the HRSN screening tool; refer to tobacco cessation for those who screen positive.
 - Alcohol screening captured through the HRSN screening tool.
 - *Patient Activation Measure (PAM) screening* entered into the Flourish tool administered by Insignia Health, document completion into care plan.
 - *Required Intake Questions* administered by the MOM case manager to fulfill data collection requirements; the MOM CCM includes questions to be asked at intake (or in third trimester once rapport is established).
 - OUD screening required only for participants who self-attest their OUD, using the screening provided in Appendix B of this case management manual. Based on DSM-V criteria, specify if level of severity is mild, moderate, or severe and if in remission.

- Care coordination activities
 - o Provide referrals based on identified areas of need
 - Ensure needed medical appointments are made for the upcoming month, such as prenatal care visits and specialty behavioral health care visits
 - Coordinate care and establish and/or increase communication between/among participant's providers across systems of care, including with the BH ASO's care coordinators, as needed
- Documentation
 - Create new case in MOM CCM for the participant and populate.
 - Log into CRISP ULP and access the patient snapshot where participants' providers and clinical conditions are captured and add relevant information.
 - Indicate that informed consent has been signed in Care Coordination Module
 - Save a hard copy of the signed consent, outside data template and PHQ-9 (if administered) GAD-7 and OUD (if participant self-attests) screenings in a secure place
 - Note: The PHQ-9 and GAD-7 screenings will be linked via PDF within the CCM but will also need to be administered and stored outside of the CCM.
 - Document completed tasks into the module (consent, initial MOM care plan, screenings provided, contact information, care team, patient visit and contact type)
 - If participant must self-attest to OUD: Document dates of MCO and ASO verification checks, date OUD screening tool administered and level of severity of OUD
 - Note: OUD screening will be stored outside of the CCM. All documentation related to this screening will be documented in the Medications & Clinical Conditions section of the MOM Initial Care Plan until otherwise specified.

During Enrollment: Second month of MOM participation through 60 days postpartum

Participants will be engaged in MOM model services from the time of enrollment up to the infant's first birthday so long as the MOM model participant remains enrolled in Medicaid and continues to meet the following requirements to be considered active.

Requirement 1: Monthly Case Management Visits and Model Requirements

On a monthly basis, MOM case managers will be expected to fulfill at least one of the five core components of the Maryland MOM model in, at a minimum, the following ways:

- 1. Comprehensive Case Management
 - o Initial needs assessment and SDOH screening

- Development and periodic reassessment of MOM care plan
- Supportive shared decision-making process to understand and select from the landscape of health-related social needs resources
- 2. Care Coordination
 - Appropriate linkages to somatic and behavioral health providers as identified within care plan for the MOM model participant
 - Following up on needed services and supports
 - Serving as the established MOM case manager for different providers and CSOs serving the MOM model participant
- 3. Health Promotion
 - Discussing recurrence of symptoms and creating a safety plan
 - Providing naloxone to the participant and educating friends/family on use of naloxone
 - o Providing literature on Maryland Crisis Connect
 - Available 24/7 to people in need of crisis intervention, risk assessment for suicide, overdose prevention, support, guidance and information or linkage to community behavioral health providers
 - Discussing options for family planning
 - Nutritional counseling
 - o Wellness programs
 - Education about STIs and other infectious diseases; e.g., viral hepatitis and HIV/AIDS Preventive healthcare education
 - Assisting with medication adherence
 - Educating family regarding appropriate infant developmental milestones and healthy attachment behaviors
- 4. Individual and Family Supports
 - With participant permission, involving partner and/or family in care activities
 - Training family about the role of recurrence of use and use of naloxone
 - Connecting families and children with needed supports such as parenting classes or family counseling
- 5. Linkages to Community and Support Services
 - Connecting participants to resources related to the SDOH screening by completing warm handoffs with programs embedded in LHDs as well as LBHAs and CSOs, such as disability benefits, social services, SUD treatment, housing, legal services, life skills training and educational/vocational training and using CRISP's envisioned referral and community resources platform

The MOM case manager will be responsible for at least one case management encounter per month. If conducting MOM case management via telehealth, the MOM case manager must document how they fulfilled each case management core components in the Care Coordination Module under the 'Monthly Contact' tab, by adding the date that each core component was addressed, plus a description in the text box. If a particular core component was not appropriate for a given month, the case manager must document the reason for not providing it.

Requirement 2: Monthly Health Service Utilization

MOM case managers will need to ensure MOM model participants receive at least one behavioral health and/or somatic health visit each month in addition to conducting monthly case management contacts. Examples of behavioral health and somatic health visits are included in Table 1 below.

Behavioral Health Visits	Somatic Health Visits
Alcohol and/or drug assessment	Primary Care
SBIRT	Specialty Care
Individual Therapy and/or Group Therapy	Federally qualified health center (FQHC) or other clinic services
Family psychotherapy and psychoeducation	Family Planning
Medication Management	Dental services for pregnant individuals through date of delivery
Opioid maintenance therapy for individuals 18 years or over	 Habilitation Services for Expansion Populations: (1) Physical therapy; (2) Occupation therapy; and (3) Speech therapy
Intensive Outpatient (ASAM Level 2.1)	OB/GYN Care- Prenatal, perinatal, and postpartum care visits
Partial Hospitalization (ASAM Level 2.5)	Labor and Delivery services
Ambulatory Detox	Newborn Care and Well Child visits

Table 2. Qualifying Monthly Visits, by Behavioral and Somatic Health Categories

*Please note that provision of MOUD does not qualify as a behavioral health visit under the MOM model.

Periodic Re-assessments of Screenings and Care Plan

To identify early recurrence of use and prevent fatal overdose, MOM case managers will screen participants for both postpartum depression as well as SUD. Please refer to Appendix D for the frequency of re-assessments for each screening.

Documentation

- Document completed tasks into the module (re-assessment of participant goals and indicated barriers, screenings provided (including an indication substance use screening was administered postpartum), contact information, care team, patient visit and contact type)
- Store outside, PHQ-9 (if administered), SUD, and GAD-7 screenings in a secure location

- Document model core elements provided during visits including health promotion activities surrounding screening for SUD and naloxone distribution provided after delivery
- Document any contact attempts and type of outreach made when participant misses appointments and case management visits

During Enrollment: 60 days postpartum through infant's first birthday

Enhanced MOM model case management services will continue until the end of the month of infant's first birthday, unless the MOM participant elects to leave the model early.

Monthly CM Visits and Model Requirements

 MOM case managers will still need to ensure they are providing monthly case management visits and fulfilling at least one of the five core elements for the remainder of the participant's time in the MOM model. MOM case managers will need to ensure MOM model participants receive a minimum of one behavioral health or somatic health visit each month in addition to conducting monthly case management contacts.

Re-assessments of Screenings and Care Plan

- *Care Plan* Re-assess participants needs and goals and revisit care plan on a monthly basis and update goals as needed
- *HRSN Tool* Re-administer screening after 60 days postpartum every three months or as needed. Administered a final time during the last month of a participant's enrollment
- *Required Postpartum Questions* – administered by the MOM case manager to fulfill data collection requirements; the MOM CCM includes questions to be asked within 60 days of the postpartum period

Documentation

- Document tasks into the MOM CCM (consent, re-assessment of participant goals and indicated barriers, screenings provided, contact information, care team, patient visit and contact type)
- Store PHQ-9 (if administered) screening in a secure location
- Document model core elements provided during visits
- Document any contact attempts and type of outreach made when participant misses appointments and CM visits

Disengaged Participants and Outreach Process

Multiple periods of up to two months if MOM model participants are lost to follow-up

Substantial outreach is a specific protocol for reengaging MOM model participants that MOM case managers will follow in the event that MOM model participants become disengaged from care (e.g. miss a doctor's appointment or miss a monthly MOM case manager contact). With documentation logging the date and type of each contact attempt described in additional detail below, MCOs will receive a PMPM payment for providing substantial outreach for disengaged

Highlight: Enrolled MOM participants who enter inpatient treatment

If an already-enrolled MOM participant enters inpatient treatment for a month or longer—and case management activities are not possible—MCOs are not eligible for PMPM payments for that month. Upon discharge, MOM participants may continue in the model without needing to re-perform intake activities but may conduct reassessments to inform an updated care plan.

beneficiaries for up to two months. There are a variety of loss-to-follow-up activities that the Department will accept to continue the PMPM payment.

MOM case managers will need to follow outreach guidelines for enrolled participants when they first become disengaged from services. Before transitioning a participant to the substantial outreach phase of participation, MOM case managers will need to make three contact attempts, to be logged in CRISP-based care coordination module:

- First attempt using preferred method of contact as identified in the Maryland Health Connection
- Others may include phone, email, mail, and home drop by visits


If participants can still not be re-engaged after following the above procedures, they will be considered lost to follow-up and provided two months' worth of substantial outreach. Potential outreach strategies may include the following:

- Use Healthy Families America and Nurse-Family Partnership home visiting model protocols;
- Contacting participants' family members, friends, partners, and emergency contacts via phone multiple times at different times of day;
- Sending mail correspondence to the participant's home or listed addresses;
- Deploying assigned MOM case manager or other assigned care plan team members (*i.e.,* CPRS and/or CHWs) to the participant's home and/or community, including on evenings or weekends;
- Contacting participant's primary care provider and other providers to assist with reengagement;

- Connecting with local ACCUs or other connected departments and community programs participant is involved with (i.e. DPSCS; DHS);
- Monitoring CRISP hospital utilization alerts to check inpatient admissions and emergency encounters; and
- Log three attempts at minimum per month into the care coordination module. The three attempts should be at least two different types of follow-up, such as two phone calls and one letter in the mail. The third attempt could also involve other systems as demonstrated in the following visual.
- See also: Participant Engagement Strategies Brief

To qualify for a PMPM payment, substantial outreach activities must be conducted and documented during each month, for multiple periods of up to two consecutive months.





Discharge Planning

Last month before infant's first birthday or at case closure¹⁷

- Conduct final case management visit, providing at least one core model component
 - Linkages (wrapping up connecting MOM model participant to social needs)

¹⁷ Discharge planning activities do not need to be completed if a MOM model participant is being discharged due to reasons other than completing services such as loss to follow-up. Ensure all outreach attempts are logged into the module and follow only the documentation section in these instances.

- Health promotion (*e.g.*, providing naloxone; family planning materials)
- Care coordination and warm handoffs
- Assess outstanding needs
 - *Care Plan* Review developed goals, determine areas that may need continued support, and provide a discharge plan to participant upon the end of services
 - *HRSN Tool* Final screening and referrals
 - Anxiety screening If needed
 - *Depression screening* Provide linkages to on-going supports if positive screening
- Documentation
 - Document all tasks and relevant screenings into the MOM CCM
 - Store any outside forms collected, PHQ-9 (if administered) and GAD-7 screenings in a secure location
 - Indicate status of MOM enrollment and notate if participant was discharged due to loss to follow-up or if they completed services
 - o Submit care alert indicating participant is no longer active

Appendix A: Eligibility Checklist for MOM Model Enrollment

For use by MOM case managers as needed to confirm clinical eligibility for potential participants before enrolling them in the MOM model.

□ Confirm participant is a Maryland state resident residing in a MOM service area □ Confirm participant is a current HealthChoice member □ Confirm participant pregnancy status is current □ Confirm participant has an Opioid Use Disorder diagnosis ✓ Check historical records of MCO claims (see Appendix B in the Case Management Manual for ICD-9 and ICD-10 codes) or ✓ If not confirmed through MCO claims, engage the BH ASO to confirm OUD diagnosis through BH ASO data or ✓ If not confirmed through either MCO or ASO data, OR indicated in the Maryland Prenatal Risk Assessment (MPRA), administer the OUD screening during intake (see Appendix B in the Case Management Manual for DSM-V criteria) and document in MOM CCM the following information: • Dates of data checks by MCO and BH ASO; • Date OUD screening tool administered; and • Level of severity of OUD. □ Confirm with the BH ASO completion of the Part 2 Release of Information If not completed, collaborate with the BH ASO to have the ROI signed

• If refusal to sign, please contact the MOM team at MDH

Appendix B: OUD Diagnosis Criteria for Self-Report of History with OUD

Diagnostia Critoria

These criteria should be applied for potential MOM participants who do not have a clinical history of an OUD diagnosis or have indicated opioid use in the Maryland Prenatal Risk Assessment. Complete screening tool and document level of severity into the MOM CCM. If clinically-licensed to provide a diagnosis, MOM case managers should see Appendix C for clinical diagnosis codes.

Diagnostic Criteria A. A problemation	c pattern of opioid use leading to clinically significant impairment or
-	anifested by at least two of the following, occurring within a 12 month
period:	
periou.	
Check all that apply	
	Opioids are often taken in larger amounts or over a longer period of time than intended.
	There is a persistent desire or unsuccessful efforts to cut down or control opioid use.
	A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects.
	Craving, or a strong desire to use opioids.
	Recurrent opioid use resulting in failure to fulfill major role obligations at work, school or home.
	Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids.
	Important social, occupational or recreational activities are given up or reduced because of opioid use.
	Recurrent opioid use in situations in which it is physically hazardous.
	Continued use despite knowledge of having a persistent or recurrent
	physical or psychological problem that is likely to have been caused or exacerbated by opioids.
	Tolerance, as defined by either of the following: (a) a need for markedly increased amounts of opioids to achieve
	intoxication or desired effect(b) markedly diminished effect with continued use of the same amount of an opioid
	Withdrawal, as manifested by either of the following:
	(a) the characteristic opioid withdrawal syndrome
	(b) the same (or a closely related) substance are taken to relieve or avoid withdrawal symptoms

DSM-V Criteria for Diagnosis of Opioid Use Disorder¹⁸

¹⁸ Criteria from American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,. Washington, DC, American Psychiatric Association page 541.

Total Number of Boxes Checked: _____

Severity:

- Mild: 2-3 symptoms
- Moderate: 4-5 symptoms
- Severe: 6 or more symptoms

Specify if:

In early remission: After full criteria for OUD were previously met, none of the criteria for OUD have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, "Craving, or a strong desire or urge to use opioids," may be met).

In sustained remission: After full criteria for OUD were previously met, none of the criteria for OUD have been met for at any time during a period of 12 months or longer (with the exception that Criterion A4, "Craving, or a strong desire or urge to use opioids," may be met).

Appendix C. OUD ICD-9 and ICD-10 Diagnosis Codes and Description

ICD-9 codes included, as the MOM model does dictate a historical timeline for OUD diagnosis without constraints to when a diagnosis occurred.

Code and Description	on
ICD-9-CM codes	Description
30400	Opioid type dependence, unspecified
30401	Opioid type dependence, continuous
30402	Opioid type dependence, episodic
30403	Opioid type dependence, in remission
30470	Combinations of opioid type drug with any other drug dependence,
	unspecified
30471	Combinations of opioid type drug with any
	other drug dependence, continuous
30472	Combinations of opioid type drug with any
	other drug dependence, episodic
30473	Combinations of opioid type drug with any
	other drug dependence, in remission
30550	Opioid abuse, unspecified
30551	Opioid abuse, continuous
30552	Opioid abuse, episodic
ICD-10-CM codes	Description
F111	Opioid abuse
F1110	Opioid abuse, uncomplicated
F1112	Opioid abuse with intoxication
F112	Opioid dependence
F1120	Opioid dependence, uncomplicated
F1121	Opioid dependence, in remission
F1122	Opioid dependence with intoxication
F1123	Opioid dependence with withdrawal
F1124	Opioid dependence with opioid-induced mood
	Disorder
F1128	Opioid dependence with other opioid-induced disorder
F1129	Opioid dependence with unspecified opioid-induced disorder
F1190	Opioid use, unspecified, uncomplicated
F11921	Opioid use, unspecified, with intoxication
	Delirium
F1194	Opioid use, unspecified with opioid-induced
	mood disorder
F1199	Opioid use, unspecified with unspecified
	opioid-induced disorder

544400	
F11120	Opioid abuse with intoxication, uncomplicated
F11121	Opioid abuse with intoxication delirium
F11122	Opioid abuse with intoxication with perceptual disturbance
F11129	Opioid abuse with intoxication, unspecified
F1114	Opioid abuse with opioid-induced mood disorder
F1115	Opioid abuse with opioid-induced psychotic disorder
F11150	Opioid abuse with opioid-induced psychotic disorder with delusions
F11151	Opioid abuse with opioid-induced psychotic disorder with
	hallucinations
F11159	Opioid abuse with opioid-induced psychotic disorder, unspecified
F1118	Opioid abuse with other opioid-induced disorder
F11181	Opioid abuse with opioid-induced sexual dysfunction
F11182	Opioid abuse with opioid-induced sleep disorder
F11188	Opioid abuse with other opioid-induced disorder
F1119	Opioid abuse with unspecified opioid-induced disorder
F11220	Opioid dependence with intoxication, uncomplicated
F11221	Opioid dependence with intoxication delirium
F11222	Opioid dependence with intoxication with perceptual disturbance
F11229	Opioid dependence with intoxication, unspecified
F1125	Opioid dependence with opioid-induced psychotic disorder
F11250	Opioid dependence with opioid-induced psychotic disorder with
	delusions
F11251	Opioid dependence with opioid-induced psychotic disorder with
	hallucinations
F11259	Opioid dependence with opioid-induced psychotic disorder,
	unspecified
F11281	Opioid dependence with opioid-induced sexual dysfunction
F11282	Opioid dependence with opioid-induced sleep disorder
F11288	Opioid dependence with other opioid-induced disorder
F119	Opioid use, unspecified
F1192	Opioid use, unspecified with intoxication
F11920	Opioid use, unspecified with intoxication, uncomplicated
F11922	Opioid use, unspecified with intoxication with perceptual disturbance
F11929	Opioid use, unspecified with intoxication, unspecified
F1193	Opioid use, unspecified with withdrawal
F1195	Opioid use, unspecified with opioid-induced psychotic disorder
F11950	Opioid use, unspecified with opioid-induced psychotic disorder with
. 11000	delusions
F11951	Opioid use, unspecified with opioid-induced psychotic disorder with
	hallucinations
F11959	
	unspecified
F11959	Opioid use, unspecified with opioid-induced psychotic disorder,

F1198	Opioid use, unspecified with other specified opioid-induced disorder
F11981	Opioid use, unspecified with opioid-induced sexual dysfunction
F11982	Opioid use, unspecified with opioid-induced sleep disorder
F11988	Opioid use, unspecified with other opioid-induced disorder

Appendix D. Screenings Frequency and Approach

Table D1. Overview

	Approach	Intake	90 Days	Third Trimester	Postpartum
HRSN	Modified AHC tool	Х		Х	Х
Depression	Embedded in HRSN, with additional requirements in the case of a positive result	Х		Х	Х
Anxiety	GAD-7	Х			Х
Tobacco	Embedded in HRSN	Х		Х	Х
Alcohol	Embedded in HRSN	Х		Х	Х
PAM	Flourish tool	Х	Х		
SUD	NIDA-Modified ASSIST				Х
Self-Report	Embedded in MOM CCM Screens	Х		Х*	Х

*If not captured at intake.

Health-Related Social Needs (HRSN)

Administer modified Accountable Health Communities HRSN Tool accessed via CRISP.

Timing: Administered within 7 days of model enrollment, a second time during the participant's third trimester, then a third time after the end of pregnancy within 60 days postpartum. Subsequent screenings administered every three months or as needed for participants who continue to be enrolled in Medicaid.

Depression

Captured through HRSN screening tool using the same screening and scoring methodologies as the PHQ-2; for those who screen positive (score of 3 or above on PHQ-2 questions) administer the remaining 7 questions of the PHQ-9 (captured and stored separately) and create a follow-up plan.

Timing: Administered as part of the HRSN tool within 7 days of model enrollment, during the third trimester, and at the end of pregnancy within 60 days postpartum. Subsequent screenings administered as needed as part of the HRSN screening cadence for participants who continue to be enrolled in Medicaid. Repeat the same procedure in deploying the PHQ-9 screening if a participant screens positive and create a follow-up plan for those participants.

Anxiety

Captured through GAD-7 screening (stored separately), with indication of participant's level of anxiety documented.

Timing: Administered at a minimum within 7 days of model enrollment and after the end of pregnancy within 60 days postpartum. Subsequent screenings administered as needed for participants who continue to be enrolled in Medicaid.

Tobacco

Capture through HRSN screening tool; added questions inquiring into the number of cigarettes smoked, in the case of a positive result. Refer to tobacco cessation for those who screen positive.

Timing: For beneficiaries who enroll in the MOM Model during their first or second trimester, it is recommended an additional tobacco screening be completed during the third trimester. In total, these beneficiaries should receive at least three screenings: within 7 days of Model enrollment, during the third trimester, and within 60 days after the end of pregnancy. Subsequent screenings administered as needed as part of the HRSN screening cadence for participants who continue to be enrolled in Medicaid.

Alcohol

Capture through HRSN screening tool.

Timing: Administered at a minimum within 7 days of model enrollment, during the participant's third trimester, and after the end of pregnancy within 60 days postpartum. Subsequent screenings administered as needed as part of the HRSN screening cadence for participants who continue to be enrolled in Medicaid.

Patient Activation Measure

Enter directly into the Flourish tool administered by Insignia Health, document completion into Care Coordination Module.

Timing: Administered within 7 days of model enrollment and a follow-up at least 90 days from initial assessment.

SUD (NIDA-Modified ASSIST)

Administered through the NIDA-Modified ASSIST screening tool (stored separately), document completion and any interventions offered as a result of participant's score into Care Coordination Module.

Timing: Administered once within 60 days after the end of pregnancy.

Self-Report Questions

Administered by the MOM case manager, document for data collection purposes.

Timing: Administered at intake (Q1-11) and within 60 days postpartum (Q12-25). More sensitive questions may be asked in the third trimester when rapport has been established.

Appendix E: Health-Related Social Needs, Depression, Anxiety, Self-Report Questions and SUD Screenings

Health-Related Social Needs

(Accessed via CRISP)

Question	Response
Domain: Living Situation	
What is your living situation today?	I have a steady place to live
	I have a place to live today, but I am worried about losing it in the future
	I do not have a steady place to live (I am temporarily staying with others, in a hotel, in a shelter, living outside on the street, on a beach, in a car, abandoned building, bus or train station, or in a park)
Think about the place you live. Do you have problems with any of the	Pests such as bugs, ants, or mice
following? CHOOSE ALL THAT	Mold
APPLY	Lead paint or pipes
	Lack of heat
	Oven or stove not working
	Smoke detectors missing or not working
	Water leaks
	None of the above
Domain: Food	
Some people have made the following statements about their food situation. Please answer	Often true
whether these statements were	Sometimes true
OFTEN, SOMETIMES OR NEVER true for you and your household in the last 12 months.	Never true
Within the past 12 months, you worried that your food would run out before you got money to buy more.	
Within the past 12 months, the	Often true
food you bought just didn't last and	
you didn't have money to get more.	Sometimes true
	Never true
Domain: Transportation	·

In the past 12 months, has lack of	Yes
reliable transportation kept you	
from medical appointments,	
meetings, work or from getting to	
things needed for daily living?	No
Domain: Utilities	
In the past 12 months has the	Yes
electric, gas, oil, or water company	
threatened to shut off services in	
your home?	No
	Already shut off
Domain: Safety	
* A score of 11 or more when the nur	nerical values for answers to the following questions posed in this
domain are added indicates a positive	e result that the person might not be safe.
Because violence and abuse	Never (1)
happens to a lot of people and	
affects their health, we are asking	Rarely (2)
the following questions.	Sometimes (3)
	Fairly often (4)
How often does anyone, including	Frequently (5)
family and friends, physically hurt you?	
How often does anyone, including	Never (1)
family and friends, insult or talk	
down to you?	Rarely (2)
,	Sometimes (3)
	Fairly often (4)
	Frequently (5)
How often does anyone, including	Never (1)
family and friends, threaten you	
with harm?	Rarely (2)
	Sometimes (3)
	Fairly often (4)
	Frequently (5)
How often does anyone, including	Never (1)
family and friends, scream or curse	
at you?	Rarely (2)
	Sometimes (3)
	Fairly often (4)
	Frequently (5)
Domain: Financial Strain	

How hard is it for you to pay for the	Very hard
very basics like food, housing,	
medical care, and heating? Would	
you say it is	Somewhat hard
	Not hard at all
Domain: Employment	
Do you want help finding or	Yes, help finding work
keeping work or a job?	Yes, help keeping work
	I do not need or want help
Domain: Education	
Do you speak a language other than	Yes
English at home?	No
Do you want help with school or	Yes
training? For example, starting or	
completing job training or getting a	
high school diploma, GED or	No
equivalent.	
Domain: Substance Use	
	pending CMMI requirements and other new data elements.
	ing during the postpartum period to monitor for risk and provide
health education.	I
During the last month, how many	
alcoholic drinks did you have in an	I Didn't Drink in the Last Month
average week? A drink is 1 glass of	
wine, wine cooler, can or bottle of beer, shot of liquor, or mixed drink.	Less than 1 Drink a Week
beer, shot of liquor, of finked drink.	
	1 to 3 Drinks a Week
	4 to 7 Drinks a Week
	8 to 13 Drinks a Week
	14 Drinks or More a Week
	Did Not Answer/Unknown
How many times in the past 12	Never
months have you used tobacco	
products (not including electronic	Once or twice
cigarettes)?	
	Monthly
	Monthly

	Daily or almost daily
On average, how many cigarettes do you smoke per day?	(free text)
Domain: Mental Health	
the MOM depression screening requi on the first two questions posed in th the participant. After completing this	ions are equivalent to the PHQ-2 depression screening. To meet rement, if a MOM participant initially screens positive (3 or above is section), MOM case managers will conduct the full PHQ-9 with section, please administer and score the GAD-7 separately.
Over the past 2 weeks, how often have you been bothered by any of the following problems?	Not at all (0)
Little interest or pleasure in doing	Several days (1)
things?	More than half the days (2)
	Nearly every day (3)
Feeling down, depressed, or hopeless?	Not at all (0)
	Several days (1)
	More than half the days (2)
	Nearly every day (3)
Stress means a situation in which a person feels tense, restless, nervous, or anxious, or is unable to sleep at night because his or her	Not at all
mind is troubled all the time. Do	A little bit
you feel this kind of stress these	Somewhat
days?	Quite a bit
	Very much
Domain: Family and Community Sup	
If for any reason you need help with day-to-day activities such as bathing, preparing meals, shopping, managing finances, etc., do you get	I don't need any help
the help you need?	I get all the help I need
	I could use a little more help
	I need a lot more help
How often do you feel lonely or isolated from those around you?	Never
	Rarely
	Sometimes

	Often					
	Always					
Domain: Maternal Child Health						
Who can you count on for help/support during this pregnancy?	(Free text)					
Who can you talk to about stressful things in your life?	(Free text)					
Do you need daycare for your child?	Yes					
	No					
If yes, would you like help finding	Yes					
it?	No					
	Maybe later					

Depression

To be administered in the case of a positive PHQ-2 result (score of 3 or more) during HRSN.

bee	er the last 2 weeks, how often have you en bothered by any of the following blems?	Not at all	Several days	More than half the days	Nearly every day
1	Little interest or pleasure in doing things	0	1	2	3
2	Feeling down, depressed, or hopeless	0	1	2	3
3	Trouble falling or staying asleep, or sleeping too much	0	1	2	3
4	Feeling tired or having little energy	0	1	2	3
5	Poor appetite or overeating	0	1	2	3
6	Feeling bad about yourself – or that you are a failure or have let yourself or your family down	0	1	2	3
7	Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
8	Moving or speaking so slowly that other people could have noticed. Or the opposite – being so fidgety or restless that you have been moving around a lot more than usual	0	1	2	3
9	Thoughts that you would be better off dead, or of hurting yourself in some way	0	1	2	3

PHQ-9 Screening¹⁹

Total score: 1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; 20-27 severe depression

 $^{^{19}}$ PHQ9 Copyright © Pfizer Inc. All rights reserved. Reproduced with permission. PRIME-MD $^{\circledast}$ is a trademark of Pfizer Inc.

Anxiety

	er the last 2 weeks, how often have you n bothered by the following problems?	Not at all	Several days	More than half the days	Nearly every day		
1	Feeling nervous, anxious or on edge	0	1	2	3		
2	Not being able to stop or control worrying	0	1	2	3		
3	Worrying too much about different things	0	1	2	3		
4	Trouble relaxing	0	1	2	3		
5	Being so restless it is hard to sit still	0	1	2	3		
6	Becoming easily annoyed or irritable	0	1	2	3		
7	Feeling afraid as if something awful might happen	0	1	2	3		

GAD-7 Screening²⁰

Total score: 0-5 mild anxiety; 6-10 moderate anxiety; 11-15 moderately severe anxiety; 15-21 severe anxiety

²⁰ Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-7.

Self-Report Questions

These questions were previously contained in a stand-alone document; they have now been built into the CRISP-housed MOM CCM.

To be Asked at Intake - CRISP Initial Care Plan

1. Is the beneficiary receiving pharmacotherapy treatment (for OUD); if so what type of medication?

□ None

- □ Buprenorphine
- □ Naltrexone
- □ Methadone
- \Box Other
- 2. Did the beneficiary have health insurance before they became pregnant (with this pregnancy)?
 - Yes, Medicaid
 Yes, Private Insurance
 Yes, Other
 No
 Not Known
- 3. What is the beneficiary's relationship status at intake?
 - □ Married, living with spouse
 - □ Married, not living with spouse
 - \Box Living with a partner
 - \Box In a relationship, not living together
 - □ Not in a relationship right now
- 4. Does the beneficiary have a high school diploma or GED?

□ Yes □ No

- 5. Did the beneficiary use any of the following substances in the last year? Check all that apply.
 - Alcohol
 Cigarettes/Other Tobacco
 Vaping/Electronic Nicotine Delivery System
 Cannabis
 Amphetamines
 Benzodiazepine
 None

What is the beneficiary's current HIV status?

- □ Positive
- □ Negative
- □ Beneficiary declined
- $\hfill\square$ Not assessed
- 7. What is the beneficiary's current Hepatitis C status?
 - □ Positive
 - □ Negative
 - □ Beneficiary declined
 - $\hfill\square$ Not assessed
- 8. Has the beneficiary ever had a prior birth (live born or still born)?

□ Yes □ No

- 9. If the beneficiary has had a prior birth (live born or still born), what is the birthdate of the beneficiary's last baby?
 - · YYYY-MM-DD
- 10. Has the beneficiary ever experienced any of the following outcomes from a prior pregnancy? Check all that apply.
 - □ Premature (<37 weeks)
 - □ Low Birthweight (<2500g)
 - □ Stillborn infant
 - □ Infant diagnosed with NAS
 - 🗆 Unknown
 - □ None
 - □ Not applicable
- 11. If the beneficiary has been pregnant before, have they had any of the following prior pregnancy risk factors? Check all that apply.
 - □ Preeclampsia or pregnancy induced hypertension
 - □ Gestational Diabetes
 - □ Gestational Hypertension
 - □ HELLP Syndrome
 - □ Hemorrhage
 - 🗆 Other
 - \Box Unknown
 - □ None
 - □ Not Applicable

To be Asked after beneficiary rapport established - up to 60 days postpartum - CRISP Care Plan Update

12. Did the beneficiary start using any of the following before the age of 18? Check all that apply.

- □ Alcohol
- □ Cigarettes/Other Tobacco
- □ Vaping/Electronic Nicotine Delivery System

□ Cannabis

□ Amphetamines

□ Benzodiazepine

□ None

13. Has the beneficiary ever experienced any of the following? Check all that apply

- □ Sexual abuse
- Physical Abuse
- Emotional Abuse
- □ Transactional Sex
- □ None of the Above

14. Have any of the beneficiary's prior children ever been placed outside of the home?

□ Yes

- 🗆 No
- 🗆 Not Known
- □ Not Applicable

Note: For Question 13, select "none of the above" if MOM model participant declines to answer. For Question 14, select "not known" if MOM model participant declines to answer.

To be Asked Postpartum (within 60 days with PHQ-9 and HSRN screening) - CRISP Care Plan Update

15. What many weeks gestation was the infant at the time of birth?

Please express your response in number of weeks. [free text]

- 16. Did the beneficiary receive pharmacotherapy treatment (for OUD) at the time of delivery; if so what type of medication?
 - □ Not Applicable

□ Buprenorphine

□ Naltrexone

 \Box Methadone

 \Box Other

17. Did the beneficiary receive pharmacotherapy treatment (for OUD) during the postpartum period; if so what type of medication?

□ None

- □ Buprenorphine
- □ Naltrexone
- \Box Methadone
- \Box Other
- 18. Did the infant have a positive screening for NAS?
 - □ Yes □ No

🗆 Not known

19. Did the infant have a positive screening for opioids?

□ Yes □ No

🗆 Not known

20. Did the infant receive pharmacotherapy treatment (for NAS)?

- □ Yes
- 🗆 No

🗆 Not known

- 21. Did the beneficiary receive any of the following during labor to manage pain?
 - Epidural
 IV Narcotics
 Other
 No/None

22. What was the beneficiary's final delivery method for MOM pregnancy?

- 🗆 Vaginal
- □ Vaginal, induced
- □ Vaginal, augmented
- □ Vaginal, VBAC
- □ Emergency C-Section
- □ Planned C-Section

23. Did the beneficiary have their infant removed for out-of-home placement (e.g., goes to social services, then the response is yes)? *Note this is required to be reported once infant date of birth field is filled for quarterly reporting

□ Yes □ No

Note: For Question 23, select "no" if MOM model participant declines to answer.

24. What contraceptive method is the beneficiary using (or planning to use). This should be assessed at the first postpartum visit.

🗆 None

- □ Natural family planning
- □ Pull out method
- □ Barrier or spermicide
- □ Hormonal
- □ Injectable
- \Box LARC
- □ Tubal ligation
- 🗆 Other
- 🗆 Unknown

25. What method is the beneficiary using to feed their infant?

- □ Breastfeeding
- \Box Pumping breastmilk for bottle or catheter feeding
- \Box Both breastfeeding and pumping breastmilk for bottle or catheter feeding
- \Box Breastfeeding or pumping and supplementing breastmilk with formula
- \Box Formula feeding only

🗆 Unknown

Substance Use Disorder

NIDA-Modified ASSIST V2.0²¹

Name: Sex () F () M Age......

Interviewer...... Date/.....

Instructions: Patients may fill in the following form themselves but screening personnel should offer to read the questions aloud in a private setting and complete the form for the patient. To preserve confidentiality, a protective sheet should be placed on top of the questionnaire so it will not be seen by other patients after it is completed but before it is filed in the medical record.

Question 1 of 8, NIDA-Modified ASSIST	Yes	No
In your <u>LIFETIME</u> , which of the following substances have you ever used? *Note for Physicians: For prescription medications, please report nonmedical use only.		
a. Cannabis (marijuana, pot, grass, hash, etc.)		
b. Cocaine (coke, crack, etc.)		
c. Prescription stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)		
d. Methamphetamine (speed, crystal meth, ice, etc.)		
e. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)		
f. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium,Rohypnol, GHB, etc.)		
g. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)		
h. Street opioids (heroin, opium, etc.)		
 Prescription opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.) 		
j. Other – specify:		

If the patient indicates that the drug used is not listed, please mark 'Yes' next to 'Other' and continue to Question 2 of the NIDA-Modified ASSIST. If the patient says "Yes" to any of the drugs, proceed to Question 2 of the NIDA-Modified ASSIST.

²¹ The NIDA Quick Screen was adapted from a single-question screen for drug use in primary care by Smith et al. 2010 and the National Institute on Alcohol Abuse and Alcoholism's Helping Patients Who Drink Too Much: A Clinician's Guide Updated 2005 Edition. The NIDA-Modified ASSIST (NM ASSIST) was adapted from the World Health Organization (WHO) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).

Question 2 of 8, NIDA-Modified ASSIST 2. In the past three months, how often have you used the substances you mentioned (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
Cannabis (marijuana, pot, grass, hash, etc.)	0	2	3	4	6
Cocaine (coke, crack, etc.)	0	2	3	4	6
 Prescription stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.) 	0	2	3	4	6
Methamphetamine (speed, crystal meth, ice, etc.)	0	2	3	4	6
 Inhalants (nitrous oxide, glue, gas, paint thinner, etc.) 	0	2	3	4	6
 Sedatives or sleeping pills (Valium, Serepax, Ativan, Librium, Xanax, Rohypnol, GHB, etc.) 	0	2	3	4	6
 Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.) 	0	2	3	4	6
• Street opioids (heroin, opium, etc.)	0	2	3	4	6
 Prescription opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.) 	0	2	3	4	6
Other – Specify:	0	2	3	4	6

• For patients who report "Never" having used any drug in the past 3 months: Go to Questions 6-8.

• For any recent illicit or nonmedical prescription drug use, go to Question 3.

In the past 3 months, how often have you had a strong desire or urge to use (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Dail
دCannabis (marijuana, pot, grass, hash, etc.)	0	3	4	5	6
Cocaine (coke, crack, etc.)	0	3	4	5	6
Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	0	3	4	5	6
Methamphetamine (speed, crystal meth, ice, etc.)	0	3	4	5	6
Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	0	3	4	5	6
Sedatives or sleeping pills (Valium, Serepax, Ativan, Librium, Xanax, Rohypnol, GHB, etc.)	0	3	4	5	6
Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	0	3	4	5	6

Street Opioids (heroin, opium, etc.)	0	3	4	5	6
iPrescribed opioids (fentanyl, oxycodone [OxyContin, .Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	0	3	4	5	6
jOther – Specify:	0	3	4	5	6

4.	During the past 3 months, how often has your use of (first drug, second drug, etc) led to health, social, legal or financial problems?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a.	Cannabis (marijuana, pot, grass, hash, etc.)	0	4	5	6	7
b.	Cocaine (coke, crack, etc.)	0	4	5	6	7
c.	Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	0	4	5	6	7
d.	Methamphetamine (speed, crystal meth, ice, etc.)	0	4	5	6	7
e.	Inhalants (nitrous oxide, glue, gas, pain thinner, etc.)	0	4	5	6	7
f.	Sedatives or sleeping pills (Valium, Serepax, Ativan, Librium, Xanax, Rohypnol, GHB, etc.)	0	4	5	6	7
g.	Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	0	4	5	6	7
h.	Street opioids (heroin, opium, etc.)	0	4	5	6	7
i.	Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	0	4	5	6	7
j.	Other – Specify:	0	4	5	6	7

5.	During the past 3 months, how often have you failed to do what was normally expected of you because of your use of (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a.	Cannabis (marijuana, pot, grass, hash, etc.)	0	5	6	7	8
b.	Cocaine (coke, crack, etc.)	0	5	6	7	8
c.	Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	0	5	6	7	8
d.	Methamphetamine (speed, crystal meth, ice, etc.)	0	5	6	7	8
e.	Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	0	5	6	7	8
f.	Sedatives or sleeping pills (Valium, Serepax, Ativan, Librium, Xanax, Rohypnol, GHB, etc.)	0	5	6	7	8
g.	Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	0	5	6	7	8
h.	Street Opioids (heroin, opium, etc.)	0	5	6	7	8
i.	Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	0	5	6	7	8
j.	Other – Specify:	0	5	6	7	8

Instructions: Ask Questions 6 & 7 for all substances ever used (i.e., those endorsed in the Question 1).

6.	Has a friend or relative or anyone else <u>ever</u> expressed concern about your use of (first drug, second drug, etc)?	No, never	Yes, but not in the past 3 months	Yes, in the past 3 months
a.	Cannabis (marijuana, pot, grass, hash, etc.)	0	3	6
b.	Cocaine (coke, crack, etc.)	0	3	6
с.	Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	0	3	6
d.	Methamphetamine (speed, crystal meth, ice, etc.)	0	3	6
e.	Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	0	3	6
f.	Sedatives or sleeping pills (Valium, Serepax, Xanax, Ativan, Librium, Rohypnol, GHB, etc.)	0	3	6
g.	Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	0	3	6
h.	Street opioids (heroin, opium, etc.)	0	3	6
i.	Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	0	3	6
j.	Other – Specify:	0	3	6

7.	Have you ever tried and failed to control, cut down or stop using (first drug, second drug, etc)?	No, never	Yes, but not in the past 3 months	Yes, in the past 3 months
a.	Cannabis (marijuana, pot, grass, hash, etc.)	0	3	6
b.	Cocaine (coke, crack, etc.)	0	3	6
c.	Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	0	3	6
d.	Methamphetamine (speed, crystal meth, ice, etc.)	0	3	6
e.	Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	0	3	6
f.	Sedatives or sleeping pills (Valium, Serepax, Xanax, Ativan, Librium, Rohypnol, GHB, etc.)	0	3	6
g.	Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	0	3	6
h.	Street opioids (heroin, opium, etc.)	0	3	6
i.	Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	0	3	6
j.	Other – Specify:	0	3	6

Instructions: Ask Question 8 if the patient endorses any drug that might be injected, including those that might be listed in the other category (e.g., steroids). <u>Circle appropriate response</u>.

8.	Have you ever used any drug by injection	No, never	Yes, but not in	Yes, in the past 3
	(NONMEDICAL USE ONLY)?		the past 3	months
			months	

- Recommend to patients reporting any prior or current intravenous drug use that they get tested for HIV and Hepatitis B/C.
- If patient reports using a drug by injection in the past three months, ask about their pattern
 of injecting during this period to determine their risk levels and the best course of
 intervention.
 - If patient responds that they inject once weekly or less OR fewer than 3 days in a row, provide a brief intervention including a discussions of the risks associated with injecting.
 - If patient responds that they inject more than once per week OR 3 or more days in a row, refer for further assessment.

Note: Recommend to patients reporting any current use of alcohol or illicit drugs that they get tested for HIV and other sexually transmitted diseases.

Tally Sheet for scoring the full NIDA-Modified ASSIST:

Instructions: For each substance (labeled a–j), add up the scores received for questions 2-7 above. This is the Substance Involvement (SI) score. Do not include the results from either the Q1 or Q8 (above) in your SI scores.

Substance Involvement Score	Total (SI SCORE)
Cannabis (marijuana, pot, grass, hash, etc.)	
Cocaine (coke, crack, etc.)	
Prescription stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	
Methamphetamine (speed, crystal meth, ice, etc.)	
Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	
Sedatives or sleeping pills (Valium, Serepax, Xanax, Ativan, Librium, Rohypnol, GHB, etc.)	
Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	
Street Opioids (heroin, opium, etc.)	
Prescription opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	
Other – Specify:	

To determine patient's risk level based on his or her SI Score, see the table below:

Level of risk associated with different					
Substance Involver	Substance Involvement Score ranges for				
Illicit or nonmedical	Illicit or nonmedical prescription drug use				
0-3	Lower Risk				
4-26	Moderate Risk				
27+	High Risk				

Appendix F: MOM Care Coordination Module Screenshots

Intake Screen

MOM Care Plan

Date of Birth Gender Address	Testxxx, Tommy 05/04/1975 M 786 Clark Kent Hwy				
City State	Testopia MD				
' indicates required field					
Patient Details					
Number of Infant Children*					
/ledicaid ID # *	Race *		Ethnicity *		
83		~			~
hone *	Email			Preferred Co	ontact Method *
OK to leave voicemail?					
mergency Contact Vame *			Phone *		
Consent					
Date Completed *					
mm/dd/yyyy	•				
Enrollment					
Enrollment Date *		Assessment Completed	÷		Initial Treatment Completed

Participant Goals & Identification of Barriers

Goal 1 *

What is the beneficiary's relationship s	status at intake? *
~	
Does the beneficiary have a high scho	ol diploma or GED? *
~	
Did the beneficiary use any of the fol	lowing substances in the last year? Check all that apply. *
Alcohol	Cannabis
Cigarettes/Other Tobacco	□ Amphetamines
Vaping/Electronic Nicotine	Benzodiazepine
Delivery System	□ None
What is the beneficiary's current HIV s	status? *
×	
What is the beneficiary's current Hepa	titis C status? *
~	·
Has the beneficiary ever had a prior b	irth (live born or still born)? *
~	
If the beneficiary has had a prior birth	(live born or still born), what is the birthdate of the beneficiary's last baby? *
mm/dd/yyyy	
Has the beneficiary ever experienced	any of the following outcomes from a prior pregnancy? Check all that apply. *
Premature (less than 37 weeks)	Unknown
□ Low Birthweight (less than 2500g)	□ None
Stillborn infant	Not applicable
\square Infant diagnosed with NAS	
If the beneficiary has been pregnant l	before, have they had any of the following prior pregnancy risk factors? Check all that apply. *
Preeclampsia or pregnancy	Hemorrhage
induced hypertension	□ Other
Gestational Diabetes	Unknown
Gestational Hypertension	□ None
□ HELLP Syndrome	Not applicable

Submit

Ongoing Screen

MOM Care Plan

MOM Care Plan Ongoing

Patient Name	GRAPE, GILBERT
Date of Birth	01/01/1984
Gender	М
Address	4145 EARL C ADKINS DR
City	RIVER
State	WV

* indicates required field

Patient Details

Medicaid ID # *	Race *	E	thnicity *	
1111 🕮	White	~	Not of Hispanic, Latino, or Spar	nish origin 🗸
Phone *	Email		Preferred Contact M	ethod *
222222222	test@test.	com	Email	~
OK to leave voicemail?				
Emergency Contact Name *		F	hone *	
test test			111111111	
Consent Date Completed * 08/18/2021	Date Rescinded mm/dd/yyyy			
MCO Contact				
Status *	~			
	thly Contact Attempted *	MCO Case Ma	mager Monthly Contact Complet	ted *
● Yes ○ No		O Yes 💿 N	lo	

Contact Date *		Contact Type (select at least one) *	
mm/dd/yyyy	٥	 Comprehensive Case Management Health Promotion Linkages to Community and Support Services 	 Care Coordination Individual and Family Support Contact attempted but not successful
Contact Date		Contact Type	
mm/dd/yyyy		 Comprehensive Case Management Health Promotion Linkages to Community and Support Services 	 Care Coordination Individual and Family Support Contact attempted but not successful
Contact Date		Contact Type	
mm/dd/yyyy	٥	Comprehensive Case Management Health Promotion Linkages to Community and Support Services	 Care Coordination Individual and Family Support Contact attempted but not successful

Screening Reassessment

Please see MOM Case Management Manual for frequency of screenings

PAM	Date Reassessed	SDOH	Date Reassessed
~	mm/dd/yyyy	~	mm/dd/yyyy 🗖
Depression	Date Reassessed	Depression Follow-up Plan	Follow-up Date
~	mm/dd/yyyy	~	mm/dd/yyyy 🛱
Depression Screening Result	Date Reassessed	Depression Screening Tool Age-appr	opriate
~	mm/dd/yyyy		~
Depression Screening Score		Depression Screener Used	
See MOM CM manual depression sci	eening Appendix D for		~
PHQ-9 and scoring instructions			
	Date Reassessed	Anxiety	Date Reassessed
	Date Reassessed	Anxiety 🗸	Date Reassessed mm/dd/yyyy
HRSN Screening Result			
HRSN Screening Result	mm/dd/yyyy 🗖	~	mm/dd/yyyy 🗖
HRSN Screening Result GAD-7 Screening Result	mm/dd/yyyy 🗖 Date Reassessed	Alcohol	mm/dd/yyyy 🗖 Date Reassessed
HRSN Screening Result	mm/dd/yyyy D Date Reassessed mm/dd/yyyy D	Alcohol	mm/dd/yyyy 🗖 Date Reassessed
HRSN Screening Result GAD-7 Screening Result	mm/dd/yyyy Date Reassessed mm/dd/yyyy Date Reassessed	Alcohol	mm/dd/yyyy 🗖 Date Reassessed

Encounter Type *

Select at least one of the following

Behavioral Health Visit

- $\hfill\square$ Alcohol and/or drug assessment
- SBIRT
- Individual Therapy and/or Group Therapy
- □ Family psychotherapy and psychoeducation
- \square Medication Management
- Intensive Outpatient (ASAM Level 2.1)
- Partial Hospitalization (ASAM Level 2.5)
- □ Ambulatory Detox

Somatic Health Visit

- D Primary Care
- □ Specialty Care
- Federally qualified health center (FQHC) or other clinic services
- Family planning
- Dental services for pregnant individuals through date of delivery
- Habilitation services for expansion populations: physical threapy; occupation therapy; and speech therapy
- OB-GYN care prenatal, perinatal, and postpartum care visits
- Opioid maintenance therapy for individuals 18 years or over

Care Coordination Activities/Milestones *

Select at least one of the following

- Shared relevant information with at least one other provider involved in the beneficiary's care
- □ Assessed beneficiary needs and goals
- Discussed self-management goals with beneficiary
- Reviewed beneficiary's medications
- $\hfill\square$ Consulted other providers involved in the beneficiary's care
- $\hfill\square$ Other care coordination activity
- \Box None of the above

Model Engagement Services *

Select at least one of the following

- \square Care management telephonic visits or contacts
- □ Management of medications or laboratory tests
- Breastfeeding support
- Education about OUD treatment
- Self-management care
- \square Health promotion: other
- Parenting classes
- □ Child care support
- □ Housing support
- Individual and family support: other
- Coaching or consultation to support adherence to treatment or care plan

Milestones/Additional Notes

notes

- Home visitation
- Care management and navigation
- Education about prenatal or postpartum care
- □ Education about infant care (including NAS treatment)
- Recovery skills
- Peer coaching or support
- □ Family counseling services
- Transportation support
- □ Other ancillary services
- Provision of naloxone
- □ None

Participant Goals

Goal 1						Goal Completed	Ч
						mm/dd/yyyy	
					,		
							2011
Goal 2						Goal Completed	1
						mm/dd/yyyy	۵
					11		
Goal 3						Goal Completed	ł
						mm/dd/yyyy	
					11		
Add Goal							
Recurrence of Use							
Date of Recurrence of Use	F	Referral Ma	ade for R	lecurrence (of Use		
mm/dd/yyyy	•					~	
Add recurrence of use							
Self Report							
To be asked after beneficiary ra	innort es	tablished	- up to 6	0 days post	toartum		
Did the beneficiary start using a							*
Alcohol	C	Cannab	ic				
Cigarettes/Other Tobacco		Amphet					
□ Vaping/Electronic Nicotine		Benzodi					
Delivery System		None					
Has the beneficiary ever experi Select "None of the Above" if N						ly. *	
Sexual Abuse Device Abuse		Transact					
 Physical Abuse Emotional Abuse 	L] None of	r the Abc	ove			
Have any of the beneficiary's pr	ior childr	en ever be	een place	ed outside :	of the h	ome? *	
Select "Not Known" if MOM mo						11111	
To be Asked Postpartum (with					creenin	g)	
	~						
	1						

	at the first postpartum visit.	
Please express your respor	n was the infant at the time of birth? * use in number of weeks.	
Didaha kana Grimmania		
the time of delivery; if so w	pharmacotherapy treatment (for OUD) a what type of medication? *	1
	~	
Did the beneficiary receive postpartum period; if so w	pharmacotherapy treatment (for OUD) of hat type of medication? *	luring the
	~	
Did the infant have a posit	ive screening for NAS? *	
	~	
Did the infant have a posit	ive screening for opioids? *	
	~	
Did the infant receive phar	macotherapy treatment (for NAS)? *	
	~	
Did the beneficiary receive	any of the following during labor to ma	nage pain? *
	~	
What was the beneficiary's	final delivery method for MOM pregnan	cy? *
	~	
(e.g., goes to social service	neir infant removed for out-of-home plac s, then the response is yes)? reported once infant date of birth field is	
	~	
What contraceptive metho	d is the beneficiary using (or planning to	use). *
	~	
What method is the benefi	iciary using to feed their infant? *	
	~	
00 March 1997	Manager only in the event of beneficia y died during model enrollment, please e	The second se
mm/dd/yyyy		
Model Exit		
Model Exit Date	Exit Treatment Plan	
mm/dd/yyyy	Pharmacotherapy	Crisis intervention
Junio da Jijiji D	Behavioral health counseling and	
	therapy	
	Health and behavior interventions for OUD	
	Psychotherapy: individual and	services Community psychiatric supportive
	group	treatment
	Social work services related to OUD treatment	🗆 None
	YOU REQUIRENT	

Submit

Substantive Outreach Screen

MOM Care Plan

Patient Name	Grape, Gil						
Date of Birth	01/01/198 U	34					
Gender Address		L C ADKINS DR.					
City	BIRCH RIV						
State	WV						
Patient Details							
Medicaid ID # *	Race *			Ethnicity *			
1111	White		~	Not of Hisp	anic, Latino, o	r Spanish origin	~
Phone *		Email		P	referred Conta	act Method *	
2222222222	EB	test@test.com			Email		~
test test				111111111			
Consent							
Consent Date Completed * 08/18/2021							
Date Completed * 08/18/2021 Contact Attempts Enter custom text if correc	t option is n					Dette	
Date Completed * 08/18/2021 Contact Attempts	t option is n	Date		ntact Attempt 2		Date	
Date Completed * 08/18/2021 Contact Attempts Enter custom text if correct	t option is n		Cor	stact Attempt 2		Date mm/dd/y	yyy 🗖
Date Completed * 08/18/2021 Contact Attempts Enter custom text if correct	t option is n	Date		ntact Attempt 2			yyy 🗖

Home